<DOC>
	<DOCNO>NCT02091375</DOCNO>
	<brief_summary>To investigate potential antiepileptic effect cannabidiol ( GWP42003-P ) child young adult Dravet syndrome .</brief_summary>
	<brief_title>Antiepileptic Efficacy Study GWP42003-P Children Young Adults With Dravet Syndrome ( GWPCARE1 )</brief_title>
	<detailed_description>GWEP1332 Part B recruit entirely new group subject GWEP1332 Part A . Patients fail entry criterion Part A may eligible take part Part B . Part B 1:1 randomized , double blind placebo-controlled 14-week comparison GWP42003-P versus placebo . The aim Part B ass antiepileptic efficacy GWP42003-P adjunctive antiepileptic treatment compare placebo , respect percentage change baseline treatment period study convulsive seizure frequency child young adult . Following establishment initial eligibility baseline measurement , subject enter Part B begin 28-day baseline observation period . Eligible subject randomize receive either GWP42003-P placebo 1:1 basis , titrate target dose identified Part A ( 20 mg/kg/day : confirm follow completion Part A independent Data Safety Monitoring Committee review unblinded safety pharmacokinetic data Part A ) . Subjects receive investigational medicinal product 14 week , consist titration period follow 12-week maintenance period . Efficacy safety monitor various clinic visit via telephone . After 14 week treatment , subject offer option enter open label extension study . Entry within seven day final treatment visit . Subjects immediately enter open label extension study commence down-titration taper period last 10 day . The taper period may interrupt subject wish enter open label extension study within seven-day timeframe . For subject opt enter open label extension study , follow-up telephone call make 28 day end dose weekly safety telephone call make 28-day follow-up period .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Epilepsies , Myoclonic</mesh_term>
	<criteria>Key Subject must male female age 2 18 year ( inclusive ) . Subject must document history Dravet syndrome completely control current antiepileptic drug . Subject must take one antiepileptic drug dose stable least four week . All medication intervention epilepsy ( include ketogenic diet vagus nerve stimulation ) must stable four week prior screen subject willing maintain stable regimen throughout study . Key Subject clinically significant unstable medical condition epilepsy . Subject clinically relevant symptom clinically significant illness four week prior screen randomization , epilepsy . Subject currently use past use recreational medicinal cannabis , synthetic cannabinoid base medication ( include SativexÂ® ) within three month prior study entry unwilling abstain duration study . Subject know suspected hypersensitivity cannabinoids excipients investigational medicinal product . Subjects part clinical trial involve another investigational product previous six month . There plan subject travel outside country residence study . Subjects previously randomize study . In particular , subject participate Part A study enter Part B .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>cannabidiol</keyword>
</DOC>